Table 1 Patient baseline characteristics.

From: Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry

N

113

Age (years)

66.1 ± 12.8

Sex (% female)

79.3

BMI (kg/m2)

22.7 ± 3.8

Disease duration (year)

14.0 ± 14.0

Stage (i/ii/iii/iv, %)

18.2/37.2/17.4/27.3

Class (i/ii/iii/iv, %)

17.4/57.0/24.8/0.8

ACPA positive (%)

82.1

RF positive (%)

77.1

KL-6 (U/mL)

338.7 ± 318.8

eGFR (mL/min/1.73 m2)

78.5 ± 26.9

Lymph (/µL)

1447 ± 759

Hb (g/dL)

11.9 ± 1.6

Previous targeted DMARDs (%)

71.1

Number of previous targeted DMARDsa

2.1 ± 1.3

MTX use (%)

48.3

MTX dose (mg/week)a

10.1 ± 3.0

Oral prednisolone use (%)

40.0

Oral prednisolone dose (mg/day)a

3.9 ± 2.0

DAS28-CRP

3.52 ± 1.20

TJC, 0–28

3.2 ± 3.9

SJC, 0–28

3.2 ± 3.6

PtGA, 0–100 mm

42.9 ± 28.2

CRP (mg/dL)

1.5 ± 2.2

ESR (mm/h)

39.8 ± 30.4

MMP-3 (ng/mL)

205.3 ± 276.3

PhGA, 0–100 mm

35.3 ± 23.8

mHAQ

0.67 ± 0.63

  1. Data are presented as mean ± standard deviation unless otherwise indicated.
  2. BMI Body mass index, Stage Steinbrocker’s stage, Class Steinbrocker’s class, ACPA anti-citrullinated peptide antibody, RF rheumatoid factor, KL-6 Krebs von den Lungen-6, eGFR estimated glomerular filtration rate, Lymph lymphocyte count, Hb hemoglobin level, targeted DMARDs biological or targeted synthetic disease-modifying antirheumatic drugs, MTX methotrexate, DAS28 Disease Activity Score in 28 joints, TJC tender joint count, SJC swollen joint count, PtGA patient global assessment, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MMP-3 matrix metalloproteinase-3, PhGA physician’s global assessment, mHAQ modified health assessment questionnaire.
  3. aMean among patients receiving the drug.
Back to article page